A new lab has opened in the University of Texas that is designed to service a gap in the development of new drugs and biotechnology products.
The lab was build for the purpose of rigorously testing the effectiveness and safety of new drugs as is required by the Food and Drug Administration, before drugs can be tested in a human clinical trial.
Go deeper with GlobalData
The facility, which is known as a Good Laboratory Practices (GLP) laboratory and provides assurances that procedures and documentation meet FDA standards, cost around $1 million to set up and is being funded by the university,
The University of Texas hope having a GLP will cut costs and time.
"These are the final, pivotal studies that the FDA will review before they are allowed into human trials," said executive director and chief technology officer of the university’s Drug Dynamics Institute, which overseas the lab, Janet Walkow.
The laboratory, named UT Advance, is at the Dell Pediatric Research Institute near the Dell Children’s Medical Center of Central Texas.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe university hopes the lab will also aid in the filing of patents and in reaching commercialisation agreements for pharmaceuticals and biomedical technology.
"We have outstanding preclinical research programs in drug development and targeted drug delivery," said dean of the College of Pharmacy, M. Lynn Crismon.
"This facility will help our researchers in these areas move more efficiently and effectively to get their discoveries into human trials."
The lab will be open for biotech companies and other entities outside the university.
University of Texas researchers are currently developing drugs to treat lung transplant patients and people suffering from cancer and viruses such as influenza and other diseases.
The first drug planned to be tested at the facility is inhaled immune suppressing drug capable of treating patients who have had a lung transplant.
Caption: University of Texas researchers are currently developing drugs to treat lung transplant patients. Credit: Kurhan.
